Positive TETON-2 IPF study results for Tyvaso at United Therapeutics (UTHR)

Rhea-AI Filing Summary

United Therapeutics Corporation filed a current report to highlight new clinical progress for its inhaled therapy Tyvaso (treprostinil) in lung disease. The company announced that the TETON-2 clinical study of Tyvaso Inhalation Solution in patients with idiopathic pulmonary fibrosis produced positive results, signaling a potentially important development for this difficult-to-treat condition. The detailed data were released in a press release dated September 2, 2025, which is included as an exhibit to the report.

Positive

• Positive TETON-2 IPF study results for Tyvaso may support a future label expansion into idiopathic pulmonary fibrosis, potentially broadening the drug’s commercial opportunity.

Negative

• None.

Insights

Biopharma and clinical-trial analyst

Positive TETON-2 results suggest a potentially meaningful expansion for Tyvaso.

United Therapeutics reported positive results from the TETON-2 clinical study evaluating Tyvaso Inhalation Solution in idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease, so any positive late-stage data for an existing pulmonary therapy can be strategically important, especially when the product is already commercial in related indications.

The announcement indicates that prespecified study goals were met in a way the company characterizes as positive, but this excerpt does not describe endpoints, magnitude of benefit, or safety profile. The eventual commercial impact will depend on the full dataset, regulatory feedback, and potential label expansion decisions based on these results.

Investors will likely focus on the detailed September 2, 2025 press release and subsequent regulatory interactions to understand how TETON-2 could influence Tyvaso’s use in IPF and the company’s longer-term revenue mix.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001082554 0001082554 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 2, 2025

United Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware		000-26301		52-1984749
(State or Other		(Commission		(I.R.S. Employer
Jurisdiction of		File Number)		Identification Number)
Incorporation)

1000 Spring Street
Silver Spring, MD		20910
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		UTHR		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company      ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

Item 8.01. Other Events.

On September 2, 2025, United Therapeutics Corporation issued a press release announcing positive results of the TETON-2 clinical study of Tyvaso^® (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis. The press release is attached as Exhibits 99.1 and is incorporated herein by reference.

TYVASO is a registered trademark of United Therapeutics Corporation.

Item 9.01. Exhibits

(d)  Exhibits
Exhibit No.		Description of Exhibit
99.1		Press release dated September 2, 2025
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	UNITED THERAPEUTICS CORPORATION
Dated: September 2, 2025	By:	/s/ Paul A. Mahon
	Name:	Paul A. Mahon
	Title:	General Counsel

3

FAQ

What did United Therapeutics (UTHR) announce in this 8-K filing?

United Therapeutics reported that the TETON-2 clinical study of Tyvaso Inhalation Solution in patients with idiopathic pulmonary fibrosis produced positive results, as described in a press release dated September 2, 2025.

Which drug and indication are involved in United Therapeutics' TETON-2 study?

The TETON-2 study involves Tyvaso (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis (IPF).

Where can investors find the detailed TETON-2 study results for UTHR?

Detailed information is contained in the press release dated September 2, 2025, which is attached to the report as Exhibit 99.1 and incorporated by reference.

Does this United Therapeutics filing include financial results or earnings data?

No. This report focuses on clinical study results for Tyvaso in idiopathic pulmonary fibrosis and does not present earnings or financial performance data.

Why are the TETON-2 results important for United Therapeutics (UTHR)?

Positive TETON-2 results in IPF are important because they may support expanded clinical use for Tyvaso, which could influence United Therapeutics’ future growth prospects if regulators ultimately allow a broader label.

What exhibits are attached to this United Therapeutics 8-K?

The report includes Exhibit 99.1, a press release dated September 2, 2025 describing the TETON-2 results, and an Inline XBRL version of the cover page.